TG Therapeutics Inc (STU:NKB2)
€ 15.004 -0.278 (-1.82%) Market Cap: 2.33 Bil Enterprise Value: 2.24 Bil PE Ratio: 74.36 PB Ratio: 15.79 GF Score: 73/100

Q3 2019 TG Therapeutics Inc Earnings Call Transcript

Nov 12, 2019 / 01:30PM GMT
Release Date Price: €6.73 (-7.81%)
Operator

Greetings. Welcome to TG Therapeutics' Third Quarter 2019 Financial Results and Business Update Call.

(Operator Instructions)

Please note that this conference is being recorded.

At this time, I'll turn the call over to Jenna Bosco. Jenna, you may now begin.

Jenna Bosco
TG Therapeutics, Inc. - VP of IR & Senior VP of Corporate Communications

Thank you. Good morning and welcome to our conference call regarding TG Therapeutics' Third Quarter 2019 Financial Results and Business Update. I'm Jenna Bosco, TG's Senior Vice President of Corporate Communications, and I welcome you to our conference call today.

Following our safe harbor statement, Sean Power, TG's Chief Financial Officer, will provide a brief overview of our financial results and then turn the call over to Michael Weiss, the company's Executive Chairman and Chief Executive Officer, who will provide an update on the ongoing development of our lead compounds ublituximab and umbralisib as well as an overview of our overall company standing.

Before we

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot